Get the app now for Free: Joist for iPhone

Join The Eureka Project, TR Tech, ICTAM, LSAM and MEIA  for a relaxed networking event to get to know other techies in Winnipeg.  No RSVP necessary!

• Luxalune Gastropub
• 734 Osborne St.
• 4:30pm
• No Registration required…all are welcom

http://www.winnipegfreepress.com/business/little-peg-biz-googles-to-book-hope-for-future-121551069.html

WINNIPEG, Manitoba (April 04, 2013) – Kane Biotech Inc. (TSX-V:KNE), is pleased to report that in a recently completed dog efficacy field study, StrixNB was very effective against halitosis (bad breath). The study was conducted on Sheltie dogs. Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms.
The field study was designed to evaluate the effect of StrixNB on bad breath in dogs over a period of 21 days using a Halimeter^® to measure the Volatile Sulfur Compounds (VSC) in breath samples. Five Sheltie dogs ranging in age from 2 years to 14 years were used in the study and had varying degrees of bad breath from slight odor to very strong odor. The dogs were kept on the same diet and drinking water with StrixNB added to the drinking water from Day 0 after measuring the initial VSC in their breath.

The VSC measurements were taken 8 times between Day 0 and Day 21 of the study. Dogs with the highest VSC measurements (very strong odor) showed the greatest reduction in bad breath. Day 9 of the study showed a reduction of 50% to 69% in the dogs with the strong odor. After 21 days, the VSC reduction continued to improve to 71% to 82%.The remaining dogs that had no or slight odor also showed VSC reductions but the percentage was lower as the base line was normal. Improvements were recorded in all five dogs with an average reduction of 48%. The level of VSC or halitosis is a strong diagnostic predictor of periodontal disease.

The Halimeter measurements of VSC levels were also compared with the organoleptic assessment of bad breath using judges. There was also a correlation between organoleptic scoring of bad breath and the Halimeter measurement of VSC. Thus, both the methods of measuring bad breath show that StrixNB is very effective against bad breath in dogs.

“Doggie breath has always been a challenge that pet owners have with their dogs and StrixNB is a unique product that attacks the problem head on” stated Gord Froehlich, President and CEO of Kane Biotech. “We have received numerous compliments on StrixNB’s breath freshening effect and are excited StrixNB will soon be available to pet owners across Western Canada through their local Veterinary Clinics”.

In addition to the measurement of bad breath, other observations in the test animals included a noticeable change in the teeth and gum line in the dogs with very strong bad breath and plaque had started to soften and was easily removable.

About StrixNB™

StrixNB is a safe and effective drinking water additive to help maintain and promote good dental and oral hygiene for companion animals. StrixNB is xylitol-free, made using 100% human food grade ingredients and registered with the Interim Notification Program of Health Canada for Low Risk Veterinary Health Products (NN.1Q11).

StrixNB works against dental disease-associated bacteria by altering the mouth’s environment. It breaks through dental biofilm – a highly structured, matrix-embedded microbial population – leaving bacteria otherwise inaccessible exposed for eradication by a microbial agent.

For more information about our product, please visit our website at www.strixnb.com or like us on Facebook at www.facebook.com/StrixNB.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

For more information, please contact:
Kam Thindal                                                                  Gord Froehlich
President & CEO
Pure Advertising and Marketing                                 Kane Biotech Inc,
604-488-9875 phone                                                   204-477-7592
kam@puread.ca                                                            204-453-1314 fax
ir@kanebiotech.com
www.kanebiotech.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, “forward-looking statements”).  These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions.  In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management’s current beliefs and are based on information currently available to management.  Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements.  Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane’s early stage of development,  lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers’ willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane’s filings with Canadian securities regulatory authorities, as well as Kane’s ability to anticipate and manage the risks associated with the foregoing.  Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive.  When relying on Kane’s forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements.  Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements.  Kane undertakes no obligation to update or revise any forward-looking statement.

StrixNB™, DispersinB® and Aledex® are registered trademarks of Kane Biotech Inc. All Rights Reserved 2013

http://world.einnews.com/pr_news/145210793/diamedica-receives-phase-i-ii-clinical-trial-regulatory-approval-for-dm-199-as-a-potential-treatment-for-diabetes

The study was conducted in compliance with Good Laboratory Practices (GLP) and also in accordance with the International Organization of Standardization: Biological Evaluation of Medical Devices, Part 10: Test for Irritation and Sensitization. Based on the skin irritation index (PII) for the formulation, the irritation response was negligible, thus the DispersinB-Gentamicin wound gel spray does not cause dermal erythema or edema due to skin irritation.

Kane Biotech has two DispersinB-based wound gel spray formulations in development for the topical wound care market. The first product is the DispersinB-Gentamicin wound gel spray for topical wound care in both human and veterinary applications. DispersinB-antimicrobial combinations have shown to be effective against Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-resistant Staphylococcus pseudintermedius (MRSP) associated with human and companion animal wound infections, respectively.   The second wound care product is in collaborative development with the US Army Institute of Surgical Research for combat wound infections.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
For more information, please contact:

Kam Thindal                                                                  Gord Froehlich
President & CEO
Pure Advertising and Marketing                                 Kane Biotech Inc,
604-488-9875 phone                                                   204-477-7592
kam@puread.ca                                                            204-453-1314 fax
ir@kanebiotech.com
www.kanebiotech.com

Field Nation, a company that turns social networking into actual working, and The Eureka Project, a company that specializes in accelerating sales growth for tech companies, have joined forces to grow Field Nation in Canada and to drive its sales growth there and around the world.

Field Nation has developed a platform that makes it easy to find skilled, trustworthy, and reliable independent contractors in a wide variety of fields. Companies who need to access additional talent on an as-needed basis, and contractors looking for clients can find each other at FieldNation.com. Field Nation has had extraordinary success in enabling Managed IT Services Providers to support their national and international clients, wherever they are located, by accessing qualified, local, talent. The Eureka Project has also had extensive experience in supporting the sales growth of managed IT services firms.
Field Nation is the fastest growing marketplace of its kind, and will use Eureka’s sales-related services to support its Canadian growth efforts and continued global growth plans.
The Eureka Project drives sales growth for tech companies by performing a wide-range of outsourced sales functions, including lead generation and pre-qualification, appointment booking, Direct B2B sales, and sales management for in-house teams and resellers networks. The Eureka model allows companies to rapidly scale up their sales efforts without adding overhead.
“Eureka and Field Nation appear to be philosophically similar. We have both experienced massive success in similar verticals. We both enable companies to scale up very quickly and we both only get paid for results” said Mynul Khan, Founder and CEO of Field Nation. “When we were looking for ways to immediately ramp up our sales efforts it seemed like a natural for us to work together.”
For the company wanting to provide service anywhere, anytime, Field Nation connects them with the talent and skills they need around the world. Field Nation provides a complete staffing and workflow management solution, quality assurance, project management tools, and detailed reports.
For contractors, Field Nation boasts thousands of contracting opportunities available at all time, management tools for the contractor, and complete financial reporting services. Field Nation handles all payment to contractors and provides comprehensive year-end reporting as well as scheduling and management tools.
Gary Brownstone, CEO of The Eureka Project echoes Khan’s sentiments. “The robustness and flexibility of Field Nation’s platform and the real value that the company brings to its clients attracted us to this opportunity. We are excited to launch Field Nation in Canada and to help them grow around the world.”
Field Nation was launched in 2008 to meet the needs of the rapidly growing ‘independent contractor’ segment of the workforce.
The Eureka Project was founded in 2007 with the mandate of accelerating the successful growth of technology companies.

For more information please contact:
At Field Nation
Chris Nichols
Chief Sales Officer
E: Chris.Nichols@FieldNation.com
T: 952-955-7948
www.FieldNation.com
At The Eureka Project
Gary Brownstone
President and CEO
E: gary@eurekaproject.ca
T: 204.262.6401
www.eurekaproject.ca

“We’re really excited to be partnering with the Eureka Project,” said Mike Iwasiow, Founder and CEO of BookedIN. “Their sales and marketing expertise has been instrumental in helping many local start-ups grow into world-class tech companies.”

“The companies we work with usually come to us because they’re new start-ups who are strong on the technology side, but they haven’t had a lot of business development experience,” said Eureka Project President and CEO Gary Brownstone. “Tech start-ups face some really unique challenges when it comes to sales and marketing, because often they are selling a product that customers might not fully understand. Our niche has been to help these companies capitalize on the business management end and expand the sales and marketing of their products.”

In the six years since its inception, the Eureka Project, located at the University of Manitoba’s Smart Park campus in Winnipeg, has partnered with approximately 40 local tech start-ups. Some of the more successful partnerships have included Complex Games, Manitoba’s first and largest videogame development studio, and Project Whitecard, a virtual learning and education provider who is currently partnering with the Canadian Space Agency and NASA.

BookedIN is a privately funded software company created to help other small businesses succeed and grow. BookedIN provides businesses with a free web page and a customizable scheduling tool that lets customers make and pay for bookings at any time, from anywhere in the world. BookedIN has been featured in the Google App Store and is in the Mozilla Marketplace.

http://www.winnipegfreepress.com/business/the-world-at-their-fingertips-198576541.html

Join TR Tech, ICTAM, and The Eureka Project for a relaxed networking event to get to know other techies in Winnipeg. No RSVP necessary!

• Luxalune Gastropub • 734 Osborne St. • 4:30 pm
• Join ICTAM, The Eureka Project and TR Tech for our monthly networking event – Tech Cafe.
• No registration required…all are welcome.